• cytel
    Improving the design and implementation
    of clinical trials
    Shaping the future of drug development
  • software solutions
    Comprehensive software solutions for
    designing and running your trials
    Powering your trial to success
    SOFTWARE SOLUTIONS
  • Rowing
    Succeed in your clinical development with
    our design and implementation advice
    Experience    Expertise    Innovation
    STRATEGIC CONSULTING
  • clinical research services
    Providing expertise and experience to
    get you the best information from your trial
    Getting it right the first time
    CLINICAL RESEARCH SERVICES
Cytel

Shaping the future of drug development

Software Solutions

Rigorously tested and continuously validated in practice, Cytel software is used at thousands of pharmaceutical, biotech, medical device companies, and leading independent research institutes.

Learn more
STRATEGIC CONSULTING

Cytel’s cutting-edge trial design and implementation expertise, with a specialty in adaptive trials, is helping sponsor companies of all sizes to increase success rates in clinical development.

Learn more
CLINICAL RESEARCH SERVICES

Proven product development knowledge and experience from our global multi-disciplinary teams – biostatisticians, operations experts, data managers, programmers and medical writers.

Learn more
Cyrus Mehta Talk Sldeset DIA 2015

Download Adaptive Trial DIA Session Slideset


Download Cyrus Mehta's 51st DIA Session Slideset: Adaptive Trials and Cardiovascular Outcomes Studies

Industry and regulatory experts joined session chair and Cytel president, Cyrus Mehta. Read his own presentation: "Adaptive Designs to Demonstrate Risk Reduction in CV Outcome Trials"

EnForeSys Webinar

View Product Page


Breakthrough Predictive Software: Simulation-driven Feasibility Forecasting

Like the sound of 99% confidence in your trial's enrollment plan? Use Cyel's EnForeSys to compare competing enrollment strategies, accurately forecast milestones, and identify problem areas earlier.

Agmen UK

View Event Details


Join Cyrus Mehta, other Statistical Innovation Leaders at Amgen UK for Summit on Statistical Innovations

Cytel, Amgen, and PSI bring together Industry, government and academia at 2015 Symposium: Bridging the gap between adaptive trial theory and reality.

What Clients Say

"Cytel’s work on the trial design, simulations and FDA discussions were instrumental in obtaining the regulatory acceptance for our proposed, ground-breaking methodology.

Implementation was smoother thanks to their experience with adaptive population enrichment strategies."

medicines company

--Simona Skerjanec, VP Medical Science
The Medicines Company

"Cytel’s innovative, yet practical adaptive design provided multiple favorable scenarios allowing us stage the Phase 3 VALOR leukemia treatment trial based on sample size re-estimation.

Difficult to imagine our going forward with traditional clinical trial methods alone."

sunesis

--Steven B. Ketchum, VP Research and Development
Sunesis Pharmaceuticals

"Working with Cytel allowed our team to move forward from research to reality swiftly.

We now have the tools to guide our innovative trial decision-making much more efficiently and knowledgeably."

early stage biostats

--Joe Heyes, VP
Early Stage Biostatistics Merck

"To my knowledge, Fulyzaq® is the very first approved treatment following a two-stage adaptive pivotal study.

There’s no question that without Cytel we wouldn’t have achieved that. You have been very service-oriented and responsive throughout."

napo

--Dr. Scott Harris, CMO
Napo Pharmaceuticals

"We learned controlling critical operational variables with ongoing collaboration – especially between data managers and statisticians – was crucial to trial success.

We even saved 20% by outsourcing the key data analytics, medical writing and submission preparation functions with Cytel."

raptor

--Dr. Patrice Rioux, VP, CMO
Raptor Pharmaceuticals

"The Cytel team understood precisely what we needed, and delivered quality work within a very demanding timeframe.

They did it right the first time. As a result, we provided the FDA-requested safety reports without impacting our development timelines."

sanofi

--Sylvain Nicolas, Global Head Biostatistics Phase 1 Studies
Sanofi

Software Solutions